Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–59 of 59 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Brain Receptor Occupancy in Healthy Subjects

NCT01232439
Conditions
Alcohol Dependence
Interventions
opioid receptor kappa antagonist
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Ileus, Fusion of Spine
Interventions
Naloxone
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Recruiting Not applicable Interventional Accepts healthy volunteers

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

NCT04787848
Conditions
Chronic Widespread Pain
Interventions
Relistor Injectable Product
Drug
Lead sponsor
Florida International University
Other
Eligibility
19 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 2 Interventional Results available

Investigation of Naltrexone for Pathological Gambling

NCT01057862
Conditions
Pathological Gambling
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Middletown, Connecticut • New Haven, Connecticut
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cannabis Dependence
Interventions
Long-acting injectable naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
New York, New York
Not yet recruiting Phase 3 Interventional

The Study of Brave-LC LDN Treatment Trial

NCT07916259
Conditions
Post-acute COVID-19 Syndrome
Interventions
naltrexone, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 25 Years
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Chula Vista, California • Denver, Colorado + 10 more
Conditions
Overdose, Risk Behavior
Interventions
Co-Dispensing
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Denver, Colorado
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Multi-System Analysis of Opioid Receptor Binding

NCT05528848
Conditions
Healthy, Opioid Use Disorder
Interventions
Carfentanil, C-11, Naloxone, Loperamide Hydrochloride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Buprenorphine's Dose Response Curve

NCT00460239
Conditions
Opioid-related Disorders
Interventions
Buprenorphine, Morphine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
Interventions
Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more